Palatin Technologies’ Post

🚨 Exciting Progress in Obesity Treatments 🚨 💊 The search for effective oral therapies for obesity is advancing, with promising results from two key contenders: VK2735 by Viking Therapeutics TERN-601 by Terns Pharmaceuticals who recently announced efficacy data. 📊 Achieving a ≥5% weight loss is considered a clinically meaningful response. I've put together charts showcasing the data for both of these drugs from their early-stage trials, taken once daily. 🔍 TERN-601's impressive results which it announced this week reflects its potential as a strong contender in the obesity treatment landscape. The high percentage of patients achieving significant weight loss in such a short period is encouraging and suggests that TERN-601 could quickly become a key player if its safety profile holds up in future studies. 🔬 While TERN-601 stands out for its early efficacy, VK2735 benefits from its more advanced stage of development and long-term efficacy and safety data. 🌟 Stay tuned for more updates as developments in this space continue to unfold!

New Perspective from Daniel Drucker in Science Magazine explores the potential of GLP-1 innovation to improve health outcomes in people with a range of chronic disorders. "A wide range of clinical trials is underway, with results likely to support expansion of the range of clinical indications benefiting from GLP-1 therapies. Hence, after almost two decades of the clinical use of GLP-1 for T2D and 10 years after the first GLP-1 medicine, liraglutide, was approved for weight loss in people with obesity, the next decade may bring even greater progress, introducing more powerful GLP-1 medicines while expanding the utility of GLP-1 therapeutics beyond currently established cardiometabolic disorders." https://lnkd.in/e8Pudb52

"Scientists hypothesize that GLP-1 drugs may help with #Parkinson’s by reducing #inflammation and protecting neurons from dying, which — if proven out — would be a critical new way of treating the #disease." Today's #KCRScienceRead highlights a new potential therapeutic use for an already booming class of drugs. Researchers describe the limited but promising results of a Phase 2 trial where patients with early #ParkinsonsDisease took the diabetes drug for one year. Check it out! https://lnkd.in/ghYCEHRe #KCRCRO #ClinicalTrials #Research #GLP #Innovation #Medicine #Diabetes #ObesityDrug

Amgen's MariTide, a unique contender in the obesity drug landscape, is raising eyebrows with its potential for longer-lasting weight loss compared to current frontrunners Wegovy and Zepbound. Its mechanism, activating GLP-1 while blocking GIP receptors, sets it apart, and early data hints at sustained weight loss even after stopping the drug. However, further research is crucial to confirm these findings and understand the underlying mechanism. Unlike Novo Nordisk's Wegovy and Eli Lilly and Company's Zepbound's weekly injections, MariTide is a monthly monoclonal antibody, potentially offering greater convenience and potentially lower cost. The ongoing Phase 2 trial is exploring whether weight loss can be maintained with reduced doses or less frequent administration, a strategy not currently utilized with existing drugs. This "induction-maintenance" approach, similar to treatments for other chronic conditions, could be a game-changer. While the small Phase 1 study showed an average 14.5% weight loss in patients receiving the highest dose, larger and longer trials are needed for confirmation. Notably, participants maintained 11% weight loss five months after their last dose, unlike the rapid rebound seen with other drugs. This extended effect requires further investigation, especially considering MariTide doesn't likely cross the blood-brain barrier, unlike its competitors. #amgen #novonordisk #elililly #glp1 #weightloss #wegovy #zepbound #ozempic #obesity #biotechinnovation #biotechnology #monoclonalantibodies #publichealth #realworldevidence

Boehringer Ingelheim and Zealand Pharma have just released promising results from their collaboration on a potential breakthrough treatment for NASH (Non-Alcoholic Steatohepatitis) and obesity. This collaboration represents a significant step forward in addressing two of the most pressing health challenges of our time. With the prevalence of NASH and obesity on the rise globally, this is a strong step for millions of patients worldwide. This article from Biopharma Dive goes into more details regarding the strong clinical results. #Biopharma #MedicalInnovation #NASH #Obesity #HealthcareAdvancements #BoehringerIngelheim #ZealandPharma #Research #Science #Innovation

Old is Good Exciting research highlights the benefits of phospholipid curcumin in treating nonalcoholic steatohepatitis (NASH) and chronic kidney disease (CKD). Study Highlights: * 62% of patients on Meriva® experienced NASH resolution without worsening fibrosis. * 50% saw a ≥1-stage fibrosis improvement. * 50% showed CKD regression. * Adverse events were rare. Expert Insight: "These findings suggest this formulation could significantly benefit liver and kidney health in NASH patients." - Natasha von Roenn, MD Interactive Questions and Case Studies: 1. Question: How does the phospholipid formulation of curcumin enhance its efficacy in NASH patients? Answer:The phospholipid formulation improves systemic absorption and delivery, leading to better therapeutic outcomes. 2. Case Study: A patient with NASH and stage 3 CKD is considering this medication . Discuss the potential benefits and risks based on this study. Answer: Potential benefits include higher likelihood of NASH resolution and fibrosis improvement, with the added benefit of CKD regression. Risks appear minimal as adverse events were rare. 3. Question: What implications do these findings have for the management of NASH and associated comorbidities like CKD? Answer: These findings suggest that this medication could be a valuable addition to NASH management, potentially improving both liver and kidney outcomes. Call to Action: Stay updated with the latest research in liver and kidney disease management! Share your thoughts on these promising findings. How do you think could change the treatment landscape for NASH? Poll: Do you believe this medication could become a standard treatment for NASH given these results? * Yes, definitely * Possibly, with more research * No, more evidence is needed Risk Management: Pharmacists play a crucial role in monitoring patient responses and managing potential risks, ensuring personalized and safe treatment plans. Environmental Sustainability: Incorporating sustainable practices in pharmaceutical management, including the responsible use of supplements contributes to overall environmental health. Let's continue to advance healthcare through collaboration and innovation! #NASH #LiverHealth #KidneyHealth #Curcumin #ClinicalResearch #Pharmacists #HealthcareInnovation #EnvironmentalSustainability #EgyptHealthcare References and Citations: * von Roenn, N., et al. "Effect of Phospholipid Curcumin Meriva® on Liver Histology and Kidney Disease Outcomes in Patients With NASH," Hepatology. Join the conversation and share your insights! How can we further improve patient outcomes with innovative treatments ?

First Patient Dosed in Phase 2 Clinical Study of Palatin’s Bremelanotide  Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity ·        Complete enrollment currently expected in 3Q 2024 ·        Topline results expected in 1Q calendar year 2025 ·        Additional studies under assessment for multiple metabolic conditions Data shows that 67% of patients on the popular obesity drugs discontinue use due to side effects and a plateau effect in the first year, often resulting in a rebound effect with patients gaining back most of the weight they lost. Our research coupled with emerging clinical data indicate that combining an MCR4 agonist with incretin therapeutics like tirzepatide may result in synergistic effects on weight loss allowing for increased weight loss at lower and better tolerated doses. https://lnkd.in/eJCjEZua

Roche's venture into the obesity sector is showing promising outcomes, evidenced by the initial clinical results post its acquisition of Carmot Therapeutics for $2.7 billion. Carmot, a clinical-stage biotech firm dedicated to transformative therapeutics for metabolic diseases like obesity and diabetes, caught Roche's attention with its portfolio of potential game-changers, poised to compete with industry leaders like Eli Lilly and Novo Nordisk. Notably, Roche acquired CT-388, an injectable dual GLP-1/GIP receptor agonist already in phase 1b trials. Recently released 24-week data from CT-388's trial demonstrated an average placebo-adjusted weight loss of 18.8%, with remarkable results across participants. These findings suggest CT-388's competitive edge in a crowded field. Investors responded positively, driving a 4% increase in Roche’s shares. Roche's morning release highlighted CT-388's tolerability and its potential for both obesity and type 2 diabetes. Further analysis showed promising results, especially among pre-diabetic participants. Roche's acquisition not only strengthens its presence in the obesity sector but also provides access to Carmot’s diverse portfolio of incretins, enhancing Roche’s R&D efforts across cardiovascular and metabolic diseases. This acquisition comes at a time when obesity poses a significant global health challenge, with associated comorbidities like type 2 diabetes and cardiovascular diseases. Scientific advances in incretin research offer promising avenues for treating obesity and related conditions, marking a shift in therapeutic approaches. #api #science #drugdiscovery #pharma #obesity #peptide #ozempic #diabetes #clicnicaltrials

Longitude portfolio company BioAge Labs has dosed the first patient in the STRIDES Phase 2 clinical trial to evaluate the company's lead product candidate azelaprag in combination with tirzepatide for the treatment of obesity in adults aged 55 and older. “We believe combining azelaprag, an exercise mimetic, with tirzepatide, a GLP-1/GIP receptor agonist that decreases food intake, could provide a powerful pharmacological parallel to the exercise and diet interventions that form the foundation of obesity management,” said BioAge CEO and co-founder Kristen Fortney, PhD. “The STRIDES trial aims to demonstrate that activating apelin signaling with azelaprag is a potent complementary mechanism that can deliver increased weight loss efficacy in patients on incretins. In addition, this trial will provide a direct read-through to azelaprag’s potential as an orally available small molecule to achieve efficacy on par with injectable weight loss drugs when combined with incretins in an all-oral regimen." Learn more about azelaprag and the clinical trial: https://lnkd.in/g_U9C3SN #biotech #metabolichealth #GLP1s